nach oben

Medical Oncology

Erschienen in:

01.10.2014 | Original Paper

High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer

verfasst von: Xiao Qu, Zhaofei Pang, Weiwei Yi, Ying Wang, Kai Wang, Qi Liu, Jiajun Du

Erschienen in: Medical Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

The association of the percentage composition of serum protein in patients undergoing lung resections for non-small cell lung cancer (NSCLC) with overall survival and recurrence-free survival has never been investigated. Patients were selected consecutively from the database of the Bio-Bank of Shandong Provincial Hospital. We retrospectively examined the impact of preoperative percentage composition of serum protein detected by serum protein electrophoresis on survival. Furthermore, we investigated the relationships between the potential prognostic biomarkers and clinicopathological factors. A total of 390 patients were evaluated. The higher percentage of α1-globulin in serum protein was significantly associated with histology type (p < 0.001), worse tumor status (p < 0.001) and higher pathological stage (p = 0.004). The α1-globulin percentage composition was an independent prognostic factor for overall survival (hazard ratio 1.52, 95 % CI 1.04–2.23, p = 0.03). High percentage of α1-globulin in serum protein was also related to short recurrence survival (hazard ratio 1.56, 95 % CI 1.14–2.13, p = 0.005). Our results showed that the percentage of α1-globulin in serum protein may be an independent prognostic factor in NSCLC.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin. 2013;63(1):11–30.CrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRef

Shio Y, Suzuki H, Kawaguchi T, Ohsugi J, Higuchi M, Fujiu K, et al. Carbohydrate status detecting by PNA is changeable through cancer prognosis from primary to metastatic nodal site: a possible prognostic factor in patient with node-positive lung adenocarcinoma. Lung Cancer. 2007;57(2):187–92. doi:10.1016/j.lungcan.2007.02.007.PubMedCrossRef

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17(5):1442–8.PubMed

Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129(1):87–93. doi:10.1016/j.jtcvs.2004.04.030.PubMedCrossRef

Remiszewski P, Roszkowski-Sliz K, Wiatr E, Roszkowska-Sliz B, Zych J, Kurzyna M, et al. Prognosis in limited disease (LD) small cell lung cancer (SCLC) patients according to status performance, local extension of lesions, type of treatment and the completeness of staging. Pneumonol Alergol Pol. 2003;71(3–4):139–47.PubMed

Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer. Int J Cancer. 2013;133(11):2720–5.PubMed

Salmeron D, Chirlaque MD, Isabel Izarzugaza M, Sanchez MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301–8. doi:10.1016/j.rmed.2012.06.006.PubMedCrossRef

Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous alpha 1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology. 1992;15(3):407–10.PubMedCrossRef

10.

Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85(3):765–71.PubMed

11.

Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, et al. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. J Thorac Oncol. 2011;6(2):291–5. doi:10.1097/JTO.0b013e31820213fb.PubMedCrossRefPubMedCentral

12.

El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro Endocrinol Lett. 2010;31(1):113–6.PubMed

13.

O’Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician. 2005;71(1):105–12.PubMed

14.

Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. Serum protein electrophoresis: an underused but very useful test. Digestion. 2009;79(4):203–10. doi:10.1159/000212077.PubMedCrossRef

15.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.PubMedCrossRef

16.

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.PubMedCrossRef

17.

Van der Schouw YT, Verbeek AL, Ruijs JH. ROC curves for the initial assessment of new diagnostic tests. Fam Pract. 1992;9(4):506–11.PubMedCrossRef

18.

Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283–98.PubMedCrossRef

19.

Bata J, Colobert L, Biron A, Brune J. Study of various serum proteins in lung cancer. Immunoglobulins A, G, M, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin. Ann Biol Clin (Paris). 1977;35(4):297–303.

20.

Krecicki T, Leluk M. Acute phase reactant proteins—an aid to monitoring surgical treatment of laryngeal carcinoma. J Laryngol Otol. 1992;106(7):613–5.PubMedCrossRef

21.

Amiguet JA, Jimenez J, Monreal JI, Hernandez MJ, Lopez-Vivanco G, Vidan JR, et al. Serum proteolytic activities and antiproteases in human colorectal carcinoma. J Physiol Biochem. 1998;54(1):9–13.PubMed

22.

Coakley RJ, Taggart C, O’Neill S, McElvaney NG. Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci. 2001;321(1):33–41.PubMedCrossRef

23.

Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002;110(11):1579–83. doi:10.1172/jci16787.PubMedCrossRefPubMedCentral

24.

Luft FC. Alpha-1-antitrypsin and its relevance to human disease. J Mol Med (Berl). 1999;77(4):359–60.PubMedCrossRef

25.

Faust D, Raschke K, Hormann S, Milovic V, Stein J. Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin Exp Immunol. 2002;128(2):279–84.PubMedCrossRefPubMedCentral

26.

Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem. 1997;272(13):8250–5.PubMedCrossRef

27.

Ades EW, Hinson A, Chapuis-Cellier C, Arnaud P. Modulation of the immune response by plasma protease inhibitors. I. Alpha 2-macroglobulin and alpha 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity. Scand J Immunol. 1982;15(1):109–13.PubMedCrossRef

28.

Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer. 1992;65(2):300–2.

29.

Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol. 1999;154(2):457–68.PubMedCrossRefPubMedCentral

30.

Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol. 1999;11(8):1247–52.PubMedCrossRef

31.

Muers MF, Shevlin P, Brown J. Prognosis in lung cancer: physicians’ opinions compared with outcome and a predictive model. Thorax. 1996;51(9):894–902.PubMedCrossRefPubMedCentral

32.

Kobayashi N, Usui S, Kikuchi S, Goto Y, Sakai M, Onizuka M, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012;75(2):223–7. doi:10.1016/j.lungcan.2011.06.009.PubMedCrossRef

33.

Zhao W, Yang Z, Liu X, Tian Q, Lv Y, Liang Y, et al. Identification of alpha1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis. J Int Med Res. 2013;41(3):573–83. doi:10.1177/0300060513476582.PubMedCrossRef

Titel: High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer
verfasst von: Xiao Qu
Zhaofei Pang
Weiwei Yi
Ying Wang
Kai Wang
Qi Liu
Jiajun Du
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 10/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0238-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers

Elevated level of microRNA-21 in the serum of patients with colorectal cancer

MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population

Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy

Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer

MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie